Patient dropout is the most expensive problem in GLP-1 prescribing.
Cadence gives prescribers the tools to deliver structured daily support across the full treatment journey — keeping patients engaged when they're most likely to quit.
Good afternoon
Nothing dramatic — and that's fine
Medication Level
Today's insight
The boring day is a good day. Stable is the goal — drama is not a sign of progress.
Programme
52 weeks
Full treatment journey
The problem
GLP-1 dropout is an industry-wide problem. Not a patient problem.
Research consistently shows that patients on injectable weight management medications struggle with adherence without structured support. The prescribers that solve this will win the market.
Patients drop out early.
Side effects peak in weeks 2-3. Without proactive support during this window, patients lose confidence and don't come back. Every dropout is lost revenue and a reputational risk.
Your team absorbs the burden.
Ad-hoc queries, missed injections, anxious patients calling with questions. None of this is in your workflow, and all of it costs time you don't have.
You can't evidence your service.
You're prescribing medication but flying blind on adherence, side effects, and outcomes. Without data, you can't differentiate your service or justify premium pricing.
The platform
A complete patient engagement platform. Built for prescribers running GLP-1.
For patients
Daily guidance timed to their injection cycle. Check-ins, symptom tracking, and a Q&A tool that handles questions before they become a phone call. No password, no app store — just a link.
For your team
A clinical dashboard showing who's on track, who's struggling, and who needs a call — before they drop out. Adherence data, flagged concerns, and outcome reports update as patients check in.
For your business
A GLP-1 service you can charge a premium for, backed by data you can show. Longer patient retention, higher lifetime value, and outcome evidence that differentiates you from competitors.
Why it works
Content grounded in pharmacokinetics, not generic wellness tips.
Cadence is designed around how GLP-1 medications actually work in the body. Side effects peak at specific points in the injection cycle. Our content meets patients exactly when they need it most.
Structured daily programme
Daily briefings covering the full treatment arc — from first injection through titration to maintenance and beyond. Not a one-size-fits-all leaflet, and not a programme that runs out.
Mounjaro and Wegovy specific
Different drugs, different pharmacokinetics. Tirzepatide and semaglutide have distinct absorption curves, side effect profiles, and titration schedules. Cadence handles both.
Personalised by patient context
13 contextual content modules adapt to each patient's circumstances — age, lifestyle, dietary needs, clinical context. The programme feels written for them, because it is.
SNOMED-CT coded symptom tracking
Patient-reported outcomes use clinical coding standards. This isn't a wellness diary — it's structured clinical data your clinical team can act on.
What prescribers are saying
Early feedback from clinicians and patients.
We've looked at a lot of patient support tools and nothing comes close to this. The fact that it actually follows the pharmacokinetics — the way it explains why patients feel different on day two versus day five — that's not something I've seen anyone else attempt.
Independent GP
Private Weight Management Prescriber
Adherence is the single biggest problem in GLP-1 prescribing right now. Patients start strong, hit the side effects, and just disappear. If something can keep them engaged through that first month, that changes everything for the service.
Clinical Director
Weight Management Clinic
The nausea was bad enough that I nearly stopped. What helped was understanding why — knowing it peaks on certain days and eases off on others made it feel like a process I was going through, not a problem I was stuck with.
Cadence Patient
Tirzepatide, Early Programme
Integration & compliance
Fits into your existing workflow. Meets the standards your regulators expect.
Works with any clinical system
No integration required to get started. Add patients through the portal, import a CSV, or use our API. For pharmacies on Cegedim Pharmacy Manager, we're building direct integration for automatic enrolment at point of dispense.
Supports CSV import, manual entry, and API integration. NHS Login on the roadmap.
Built for UK healthcare regulation
- ✓ Designed to MHRA Class I SaMD standards
- ✓ ICO registered (ZC095403)
- ✓ UK GDPR compliant, data hosted in London
- ✓ DCB0129 / DCB0160 clinical safety standards
- ✓ Immutable audit logs, clinician-scoped access
- ✓ Uses SNOMED-CT and dm+d medication coding
The evidence
Structured digital support improves treatment adherence. The research is clear.
Across chronic disease management, oncology, and weight management, peer-reviewed research consistently shows that patients using structured digital tools stay on treatment longer and report better outcomes than those receiving standard care alone.
Significant improvement
A meta-analysis of 14 randomised controlled trials found that mobile health apps significantly improved medication adherence across chronic conditions including cardiovascular disease, diabetes, and neurological conditions (p < 0.001).
Xiong et al., JMIR 2025; Park et al., JMCP 2020
5-month survival benefit
In oncology, patients using electronic symptom monitoring experienced a 5-month overall survival benefit, 7% fewer emergency department visits, and measurably improved quality of life compared to standard care.
Basch et al., JAMA 2017; PRO-TECT Alliance AFT-39 Trial
69% retention at 12 months
A digitally-supported GLP-1 weight management programme retained 69% of patients at 12 months, with a mean weight loss of 16.3% — significantly above rates seen in standard prescribing-only models.
Found Health, PMC 2024; JMIR Formative Research 2025
77% report better outcomes
In a systematic review of digital health interventions for chronic disease, 77% of studies reported that patients experienced improved quality of life, health outcomes, and ability to self-manage their condition.
JMIR mHealth and uHealth 2026; Systematic Scoping Review
Cadence is built on these principles — structured daily engagement, symptom monitoring with clinical coding, and proactive clinician alerts — applied specifically to GLP-1 treatment where the adherence gap is widest.
The cost of doing nothing
Every patient who drops out costs you more than the prescription.
GLP-1 treatment runs for months or years. A patient who stays the course represents ongoing consultations, repeat prescriptions, and service revenue. A patient who drops out at week 4 represents a fraction of that — plus the time your team spent onboarding them.
Weeks 2-3
When most patients experience peak side effects and consider stopping. This is the highest-risk window for dropout.
Months, not weeks
The full treatment course. Every week a patient stays engaged is another week of service revenue and clinical value for your practice.
Day 1
When Cadence starts working. Structured support begins immediately — not after the first problem, but before it.
Prescribers running structured adherence programmes consistently see longer patient retention than those relying on ad-hoc follow-up. The question isn't whether support improves retention — it's whether you're offering it.
Your prescriber has your back. So does the app.
Starting Mounjaro or Wegovy can feel daunting. Cadence keeps you connected to your prescriber, supported through every injection cycle, and never alone with a question.
Beyond treatment
104-week programmeSupport doesn't stop when the prescription does.
65% of patients stop GLP-1 treatment within a year. When they stop, every other platform goes silent. Cadence delivers 52 weeks of structured post-treatment support — because the patients who stop are the ones who need you most.
52 weeks of post-treatment support.
Evidence-based content adapted to why the patient stopped — whether they reached their goal, experienced side effects, or faced cost and supply issues. Five content paths, one clinical safety standard.
Patients come back to you.
36-47% of patients restart within a year. When they're ready, Cadence routes the restart conversation directly to your pharmacy — not to your competitors. Every restart is 16-20+ weeks of new prescriptions.
Data no one else captures.
Post-discontinuation weight trajectories, food noise scores, and quality of life data across the cessation transition. No competitor captures this. No clinical body has even published post-cessation guidelines. This is the evidence gap.
104 weeks of total support.
52 weeks on treatment. 52 weeks after. The only GLP-1 platform with structured post-treatment support. NICE requires ongoing monitoring — Cadence delivers it.
Who we work with
Built for prescribers of every kind.
Whether you're a pharmacy, private clinic, weight loss service, or multi-site group — Cadence scales to your operation.
Pharmacies
Community or online. Your team creates patients in the portal or imports from your dispensing system. Patients get a magic link, onboard themselves, and your dashboard updates in real time.
Private doctors & GPs
Add GLP-1 patient support to your practice. Structured follow-up between appointments, symptom monitoring, and outcome data — without extra admin for your team.
Weight loss clinics
Differentiate your service with structured daily patient engagement. Evidence your outcomes, reduce dropout, and give patients a reason to stay.
Aesthetics clinics
Extend your GLP-1 offering beyond the consultation room. Patients get daily guidance; you get adherence data and clinical oversight.
0
Weeks of structured daily content
0
Medications supported — Mounjaro & Wegovy
0
Contextual content modules per patient
Ready to run a GLP-1 service you're proud of?
Book a 30-minute demo and we'll show you exactly how Cadence fits into your practice — no hard sell, no setup pressure.
Book a Demo